A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
Status:
Unknown status
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation, phase I study to determine the recommended Phase 2
dose (PR2D) by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell
lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Hangzhou ACEA Pharmaceutical Research Co., Ltd. Hangzhou ACEA Pharmaceutical Research Co.,Ltd.